Matthew Alvin
The safety of iodinated and gadolinium-based contrast agents (GBCAs) has been and continues to be a hot topic in all areas of radiology, including neuroradiology. In this edition of the AJNR News Digest, we highlight several recently published articles summarizing the safety of iodine-based and gadolinium-based contrast agents used in neuroimaging. These articles provide … more »
Sheng Liu
CTA and CTP are the most frequently used noninvasive vascular imaging techniques to evaluate acute ischemic stroke (AIS).1,2 Although previous studies suggest that the risk of contrast-induced acute kidney injury (AKI) secondary to CTA/CTP imaging is relatively low in patients with AIS,1–3 the potential risk from iodinated contrast exposure is proportional to the … more »
Jin Ho Beom
Recently, with the publication of guidelines recommending active intervention for patients with acute ischemic stroke, the trend is changing with aggressive treatment in clinical practice. At this point, we wanted to predict contrast-induced acute kidney injury according to the baseline renal function, as well as present a reference value of the … more »
Ira Krefting
This study was initiated following the 2009 FDA Advisory Committee on Nephrogenic Systemic Fibrosis and the subsequent safety labeling changes contraindicating gadodiamide (Omniscan), gadopentetate (Magnevist), and gadoversetamide (Optimark) in patients with severe renal failure (estimated glomerular filtration rate [eGFR] < 30). Gadobenate (MultiHance), structurally related to gadopentetate, was not uniquely associated with nephrogenic … more »
Sasan Partovi
Our paper commented on a large retrospective observational study by Myung and colleagues investigating postcontrast acute kidney injury in patients with stroke undergoing CTA followed by cerebral angiography.1 In this study, the authors found that 9.5% (57 out of 601 patients) of included patients developed postcontrast acute kidney injury. From the patients … more »
David S. Enterline
The authors of our study have an ongoing interest in the use of gadolinium-based contrast agents (GBCAs) for neuro MRI. In January 2018, the FDA granted labeling for the use of gadobenate dimeglumine (MultiHance) in patients younger than 2 years of age, based on safety and diagnostic efficacy data collected in neonates … more »
Carlo Augusto Mallio
Investigating the safety of gadolinium-based contrast agents (GBCAs) is a fascinating task. Knowledge from physics, chemistry, and clinical imaging must be integrated in order to provide answers to research questions as well as clinical needs.
Following the evidence of intracranial gadolinium deposition after serial injections of GBCAs, several papers showed that, as … more »